Last edition
News about "Reset Pharmaceuticals"
Filament Health and Reset Pharma Enter Licensing Agreement for Botanical Psilocybin Drug Candidate
Reset Pharma will use its botanical psilocybin drug candidate, PEX010, for a phase 2 clinical trial studying demoralization syndrome.
Reset Pharmaceuticals | 01/09/2023 | By Manvi | 995
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members